Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• The erbB-2 oncoprotein is frequently overexpressed in human ovarian cancers.
• Targeting oncogenic proteins is a key strategy in cancer therapy.

Purpose of the Study:

• To develop a gene therapy approach for targeted eradication of the erbB-2 oncoprotein.
• To investigate the mechanism of action and efficacy of intracellular single-chain antibodies against erbB-2.

Main Methods:

• Gene constructs encoding anti-erbB-2 intracellular single-chain antibodies were developed.
• The cytocidal effect was evaluated in erbB-2-overexpressing human ovarian tumor cells.
• Mechanistic studies focused on the induction of apoptosis and protein localization.

Main Results:

• The gene therapy approach demonstrated a marked cytocidal effect specifically in erbB-2-overexpressing tumor cells.
• Programmed cell death (apoptosis) was identified as the mechanism of cell death.
• No cytocidal effect was observed in tumors not overexpressing erbB-2.
• Apoptosis was induced secondary to the antibody-mediated ectopic localization of the erbB-2 oncoprotein.

Conclusions:

• Selective oncogene 'knock-out' using intracellular antibodies is a novel anticancer gene therapy strategy.
• This approach offers potential for highly specific, targeted eradication of human tumor cells.
• Intracellular antibodies provide a promising tool for targeted cancer therapy by disrupting oncogenic protein function.